财务分析作业 白云山年报 英文版

FinancialanalysiscourseworkGuangzhouBaiyunshanPharmaceuticalCo.,Ltd.2010AnnualReportAnalysis————InternationalInstituteofAccounting0803TeammembersAnalysisOutline1.Introduction2.Commonratioanalysis3.RelatedRatioAnalysis4.ComparativeAnalysisofcompetitors5.Conclusions1.Introduction(1)BasicinformationofcompanyChineseCompanyName:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.NameinEnglish:GuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Chineseabbreviationofthecompany:BaiyunshanPharmaceuticalCompanyabbreviation:BYSLegalrepresentative:Mr.XieBinBoardSecretary:Mr.QiaoYongAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhone:[phone]Fax:020-87,063,699E-mail:[e-mail]SecuritiesAffairsRepresentative:MissGaoYanzhuAddress:BaiyunDistrict,GuangzhouCity,GuangdongProvince,andthestreetwith88YunxiangRoadPhone:[phone]Fax:020-87,063,699E-mail:[e-mail](2)CompanyBusinessDescriptionGuangzhouBaiyunshanPharmaceuticalCo.,Ltd.Establishedin1973,1992,GuangzhouMunicipalPeople'sGovernmentof11menstrualapprovedbytheGeneralPharmaceuticalFactory,GuangzhouBaiyunMountain,suchastheestablishmentoffivejoint-stockcompaniesthroughtherestructuringofenterprises,inNovember1993asthefirstbatchofGuangzhouCityListedcompanieslistedontheShenzhenStockExchange,nowhastotalsharecapitalof469million.Salesvolumein2007reached3.61billionyuanin2008salesvolumeofover4billionyuan.?companyfocusedonthepharmaceuticalindustry,thebusinessincludestheproductionandmanagementofavarietyofdosageformsofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicineandotherdrugs.Afteryearsofdevelopment,undertheWhiteCloudMountainatotalof12membercompanies,haveallpassedthenationalGMP,GSPcertification,GuangzhouBaiyunMountainInnovationCentreChemicalPharmaceuticalEngineeringTechnologyCenterinGuangdongProvince.?thecompanyovertheyearstobrandbuilding,establishingthefirstpharmaceuticalpreparationsinthecountryoneofthebrand,itsbrandawarenessandreputationamongconsumersinthecountryhasastronginfluence.2006WhiteCloudMountaintrademarkwasidentifiedaswell-knowntrademarksinChinain2007,wasidentifiedasfocusontraininganddevelopmentofexportsofGuangdongProvinceFamousBrandtitlebrandvaluein2008wasassessedtobe10.52billionyuan.Business:development,production,salesofChineseandWesternmedicine,chemicalrawmaterials,externaluse,children'smedicine,healthmedicine.Operationofcommercialandmaterialsupplyandmarketing.Operatingvarioustypesofgoodsandtechnologyimportandexportbusiness(exceptfornationallimitandprohibition).Managementandfeedprocessingandthethreetofillabusiness.Productionoftwotypesofclinicaltestingoftheinstrumentsanddiagnosticreagents.1.IntroductionMainoperationsbyindustrySub-industryorproductRevenueOperatingcostsGrossmargin(%)OperatingincomeoverlastyearOperatingcostoverlastyearGrossmarginoverlastyearChemicals,pharmaceuticalrawmaterialsmanufacturingindustry43,678.3539,405.269.78%26.74%30.63%-2.69%Chemicalpreparationsmanufacturing193,184.22116,208.4339.85%22.67%15.09%+3.97%ChineseherbalmedicinesandtraditionalChinesemedicineprocessingindustry82,040.3554,892.2433.09%6.48%17.72%-6.39%OtherPharmaceuticalManufacturing614.93624.58-1.57%-12.17%-31.42%+28.51%Pharmaceuticalcommoditycirculation5,684.952,449.0056.92%5.29%9.46%-1.64%Total325,202.80213,579.5134.32%18.22%18.06%+0.09%(3)2010annualoperatingresultsUnit:million一、公司介绍(3)annualoperatingresultsin2010Unit:millionMainbusinessbyproductAmoxicillin22,265.9111,471.4648.48%-3.41%6.01%+1.43%Qingkailing27,359.7613,684.5249.98%25.72%34.64%-3.32%YiliKeteling20,778.7618872.159.18%5.49%9.76%-3.53%Cephalosporinsulfideinjection26,499.1513781.0147.99%29.23%37.18%-3.02%Cefixime14,685.914273.9970.90%23.27%20.45%+0.69%CeftriaxoneAPI12,737.8312920.93-1.44%54.41%59.96%-3.52%Cefuroxime10,073.589716.133.55%13.71%16.86%-2.60%(3)2010annualmainbusinessregionsUnit:millionRegionRevenueOperatingincomeoverlastyearSouthChina153171.5715.95%EastChina40378.8130.20%NorthChina39083.7439.35%Northeast11390.0611.15%Southwest28585.8134.39%Northwest4986.6223.38%CentralChina47606.19-1.58%Total325202.818.22%二、共同比分析ComparisonofaccountingdatacalendarUnit:Yuan201020092008Totaloperatingincome3,316,861,029.182,795,105,546.582,635,870,540.72Grossprofit257,089,118.33117,617,343.45115,966,090.00Netprofitattributabletoshareholdersoflistedcompanies204,736,590.14107,765,675.4376,407,343.62DeductionattributabletoshareholdersoftheCompany'snetnon-recurringgainsandlosses163,981,242.9349,316,518.0838,644,489,063.00CashflowfromoperatingactivitiesNet327,214,424.47300,141,134.1683,532,831.99Theendof2010Theendof2009Theendof2008Totalassets3,055,310,511.652,945,054,275.462,814,309,427.45Thereforeattributabletoshareholdersoflistedcompaniestherightsandinterests1,106,532,618.04912,534,940.30804,974,766.55Equity(shares)469,053,689.00469,053,689.00469,053,689.002.CommonratioanalysisLongitudinalanalysisofthecommonratioBalanceSheetAssetsDecember31,2010December31,2009December31,2008Totalcurrentassets50.05%49.67%45.76%Totalnon-curren